

## [Dexamethasone](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.4. Hormones and antihormones](#)

ATC codes: [H02AB02](#)

EMLc

Indication

Lymphoid leukaemia, not elsewhere classified ICD11 code: [2B33.3](#)

INN

Dexamethasone

Medicine type

Chemical agent

List type

Complementary

Formulations

**Oral > Liquid:** 2 mg per 5 mL (as sodium phosphate) (EMLc)

**Parenteral > General injections > unspecified:** 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

**Oral > Solid > tablet:** 2 mg (as dexamethasone base) (EMLc) ; 4 mg (as dexamethasone base)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 2015 ([TRS 994](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Dexamethasone](#)

DrugBank

[Dexamethasone](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the listings to reflect the amount of dexamethasone in terms of dexamethasone salt or dexamethasone base.